Jubilant to Work With Endo Pharmaceuticals on Drug Development

NOIDA, India - Collaboration to Provide Endo Pharmaceuticals With New Drug Candidates in Oncology

Jubilant Organosys Ltd., headquartered in Noida, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a discovery and development collaboration with Endo Pharmaceuticals, a US-based pharmaceutical company. As part of the agreement, Jubilant and Endo would collaborate initially to develop a portfolio of targets in the area of oncology, with a focus on delivering preclinical candidates that could be selected for joint clinical development.

Endo will own any compounds developed under the collaboration and will be responsible for worldwide commercialization.

Under an initial three-year agreement, Jubilant will receive from Endo research funding and success-based development milestones and royalties on the successful commercialization of the compounds developed.

Endo Pharmaceuticals, is a specialty pharmaceutical company engaged in R&D, sales and marketing of branded and generic medicines in pain management, urology, endocrinology and oncology.

Commenting on the Collaboration, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd, said: “We are pleased to announce this collaboration with Endo Pharmaceuticals, and look forward to the prospect of contributing to Endo’s expanding discovery pipeline. We anticipate significant rewards on successful development of compounds and its subsequent commercialization. This partnership continues to demonstrate Jubilant’s mission to be India’s largest provider of innovative solutions for accelerating global drug development and enabling affordable patient care.”

Dr. Ivan Gergel M.D., Executive Vice President, Research & Development of Endo Pharmaceuticals said: “We are excited about this opportunity with Jubilant. We look forward to our collaboration with the goal of bringing new therapies and healthcare solutions to patients.”

About Jubilant Biosys

Jubilant Biosys Ltd. is a subsidiary of Jubilant Organosys Ltd., which provides integrated drug discovery and development solutions to the global pharmaceutical industry. The 120,000 sq. ft. state of the art Jubilant Biosys Discovery Center in Bangalore integrates the capabilities of over 300 scientists specializing in multiple disciplines including biology, chemistry, structural biology, pharmacology, molecular modelling, crystallography and information technology to support collaborations with global pharma companies in USA, Europe and Japan.For more information visit: www.jubilantbiosys.com

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, is the largest custom research and manufacturing services (CRAMS) and leading drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.

For more information visit: www.jubl.com

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Source: Jubilant Organosys Ltd

For further information contact: Jubilant Organosys Limited. For media, Seema Ahuja, Vice President, Corporate Marketing & Communications, Ph: +91-120-4361062, Mobile: +91-9810631779, email:seema_ahuja at jubl.com. For investors, Deepak Malik, Manager, Investor Relations, Ph: +91-120 4361114, Fax: +91-120-2516629, email: deepak_malik at jubl.com, Siddharth Rangnekar, Citigate Dewe Rogerson, Tel: +91-22-4007-5005, Fax: +91-22- 2284 4561, email:siddharth at cdrindia.com